PLPP7
Inactive phospholipid phosphatase 7
Also known as: C9orf67, FLJ14662, MGC12921, NET39, PLPP7_HUMAN, PPAPDC3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8NBV4
- Gene
- PLPP7
- Ensembl
- ENSG00000160539
- Chromosome
- 9
- Canonical length
- 271 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Vesicles
OverviewNCBI Gene
Predicted to enable sphingosine-1-phosphate phosphatase activity. Predicted to act upstream of or within negative regulation of myotube differentiation. Predicted to be located in endoplasmic reticulum membrane and nucleus. Predicted to be active in membrane and nuclear envelope. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
271 residues, UniProt reviewed canonical sequence.
>Q8NBV4|PLPP7
1 MPASQSRARA RDRNNVLNRA EFLSLNQPPK GGPEPRSSGR KASGPSAQPP PAGDGARERR
61 QSQQLPEEDC MQLNPSFKGI AFNSLLAIDI CMSKRLGVCA GRAASWASAR SMVKLIGITG
121 HGIPWIGGTI LCLVKSSTLA GQEVLMNLLL ALLLDIMTVA GVQKLIKRRG PYETSPSLLD
181 YLTMDIYAFP AGHASRAAMV SKFFLSHLVL AVPLRVLLVL WALCVGLSRV MIGRHHVTDV
241 LSGFVIGYLQ FRLVELVWMP SSTCQMLISA WLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PLPP7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 4
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 197 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 197 nTPM
- heart muscle: 87 nTPM
- tongue: 70 nTPM
- cerebellum: 16 nTPM
- cerebral cortex: 15 nTPM
- hypothalamus: 9.7 nTPM
Single-cell type
- myonuclei: 282 nCPM
- retinal bipolar cells: 223 nCPM
- retinal amacrine cells: 107 nCPM
- cardiomyocytes: 84 nCPM
- oocytes: 69 nCPM
- extravillous trophoblasts: 67 nCPM
Immune cell
- classical monocyte: 2.6 nTPM
- myeloid DC: 2.3 nTPM
- intermediate monocyte: 1.8 nTPM
- non-classical monocyte: 1.5 nTPM
- NK-cell: 1.3 nTPM
- plasmacytoid DC: 1.1 nTPM
Brain region
- cerebellum: 33 nTPM
- cerebral cortex: 29 nTPM
- thalamus: 24 nTPM
- medulla oblongata: 23 nTPM
- pons: 23 nTPM
- midbrain: 22 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.32
- gnomAD pLI
- 0.01
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PLPP7 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PLPP7 as an antibody target. Whether an autoantibody or antibody against PLPP7 could matter depends on whether native PLPP7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PLPP7 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PLPP7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...